drugset

drugset / Trial / NCT00180050

Budesonide Treatment for Lymphocytic Colitis

NCT00180050 ↗

Phase 3 Completed 40 enrolled Technical University Dresden Dr. Falk Pharma GmbH · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis

Timeline

Start: 2002-01
Primary completion: 2006-08
Completion: 2007-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Budesonide	Small molecule	—	Oral

Indications